MedTrace Logo

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

NCT06385795 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women.

Conditions

Interventions

DRUG

NOE-115

NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.

Sponsors & Collaborators

  • Noema Pharma AG

    lead INDUSTRY

Principal Investigators

  • Clinical Director, MD · Noema Pharma AG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-22
Primary Completion
2025-08-13
Completion
2025-08-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06385795 on ClinicalTrials.gov